Sign In
Buy VSTM
$3.62
-0.190 (-4.99%)
At Close: Jun 03, 2026
Verastem Oncology to Present at Jefferies Healthcare Conference
08:00am, Wednesday, 27'th May 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann
Verastem Oncology to Present at Jefferies Healthcare Conference
07:30am, Wednesday, 27'th May 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
07:30am, Tuesday, 26'th May 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appoi
Cancer Stocks That Are Advancing the Future of Oncology Care
01:01pm, Monday, 18'th May 2026
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Monday, 18'th May 2026
The heavy selling pressure might have exhausted for Verastem (VSTM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
Verastem Oncology to Present at Upcoming Investor Conferences
07:30am, Tuesday, 12'th May 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its
Verastem Q1 Earnings Call Highlights
03:12am, Saturday, 09'th May 2026
Verastem NASDAQ: VSTM reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade s
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
07:30am, Friday, 08'th May 2026
BOSTON--(BUSINESS WIRE)--Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
11:41pm, Thursday, 07'th May 2026
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
08:11pm, Thursday, 07'th May 2026
Verastem (VSTM) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.96 per share a year ago.
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
04:01pm, Thursday, 07'th May 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launc
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of “Moderate Buy” from Analysts
02:31am, Friday, 24'th Apr 2026
Verastem, Inc. (NASDAQ: VSTM - Get Free Report) has been given an average rating of "Moderate Buy" by the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One analy
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
07:30am, Thursday, 23'rd Apr 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced two-year
